


**Amendments to the Claims**

1. (Original) A compound of the formula:



wherein R represents C<sub>1</sub>-C<sub>20</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>1</sub>-C<sub>6</sub> alkylaryl, C<sub>1</sub>-C<sub>6</sub> alkyl(C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, C<sub>1</sub>-C<sub>6</sub> alkyl-N,N-C<sub>1</sub>-C<sub>6</sub> dialkylamine, C<sub>1</sub>-C<sub>6</sub> alkyl-pyrrolidine, C<sub>1</sub>-C<sub>6</sub> alkyl-piperidine, C<sub>1</sub>-C<sub>6</sub> alkyl-morpholine or a pharmaceutically acceptable salt thereof.

2. (Original) A compound according to claim 1 wherein R represents C<sub>1</sub>-C<sub>10</sub> alkyl.
3. (Original) A compound according to claim 2 wherein R represents 2-ethyl butyl, isobutyl, 3-methyl butyl, decyl, or ethyl.
4. (Original) A compound according to claim 3 wherein R represents 2-ethyl butyl,
5. (Original) A compound according to claim 3 wherein R represents isobutyl.
6. (Original) A compound according to claim 3 wherein R represents 3-methyl butyl.
7. (Original) A compound according to claim 3 wherein R represents decyl.
8. (Original) A compound according to claim 3 wherein R represents ethyl.
9. (Original) A compound which is (3*S*,4*aR*,6*R*,8*aR*)-6-[2-(1*H*-Tetrazol-5-yl)-ethyl] -1,2,3,4,4*a*,5,6,7,8,8*a*-decahydro-isoquinoline-3-carboxylic acid 2-ethyl-butyl ester, or a pharmaceutically acceptable salt thereof.

10. (Original) A compound according to claim 9 wherein the pharmaceutically acceptable salt is a trifluoroacetate salt.

11. (Original) A compound which is (3*S*,4*aR*,6*R*,8*aR*)-6-[2-(1*H*-Tetrazol-5-yl)-ethyl] -1,2,3,4,4*a*,5,6,7,8,8*a*-decahydro-isoquinoline-3-carboxylic acid isobutyl ester, or a pharmaceutically acceptable salt thereof.

12. (Original) A compound according to claim 11 wherein the pharmaceutically acceptable salt is a trifluoroacetate salt.

13. (Original) A compound which is (3*S*,4*aR*,6*R*,8*aR*)-6-[2-(1*H*-Tetrazol-5-yl)-ethyl] -1,2,3,4,4*a*,5,6,7,8,8*a*-decahydro-isoquinoline-3-carboxylic acid 3-methyl butyl ester, or a pharmaceutically acceptable salt thereof.

14. (Original) A compound according to claim 13 wherein the pharmaceutically acceptable salt is a trifluoroacetate salt.

15. (Original) A compound which is (3*S*,4*aR*,6*R*,8*aR*)-6-[2-(1*H*-Tetrazol-5-yl)-ethyl] -1,2,3,4,4*a*,5,6,7,8,8*a*-decahydro-isoquinoline-3-carboxylic acid decyl ester, or a pharmaceutically acceptable salt thereof.

16. (Original) A compound according to claim 15 wherein the pharmaceutically acceptable salt is a trifluoroacetate salt.

17. (Original) A compound which is (3*S*,4*aR*,6*R*,8*aR*)-6-[2-(1*H*-Tetrazol-5-yl)-ethyl] -1,2,3,4,4*a*,5,6,7,8,8*a*-decahydro-isoquinoline-3-carboxylic acid ethyl ester, or a pharmaceutically acceptable salt thereof.


18. (Currently Amended) A compound according to ~~claim 15~~claim 17 wherein the pharmaceutically acceptable salt is a hydrochloride salt.

19. (Original) A compound which is (3*S*,4*aR*,6*R*,8*aR*)-6-[2-(1*H*-Tetrazol-5-yl)-ethyl] -1,2,3,4,4*a*,5,6,7,8,8*a*-decahydro-isoquinoline-3-carboxylic acid ethyl ester hydrochloride monohydrate.

20. (Original) A pharmaceutical composition, which comprises a compound as claimed in Claim 1 and a pharmaceutically acceptable diluent or carrier.


21. (Original) A pharmaceutical composition for the treatment of pain or migraine, which comprises a compound as claimed in Claim 1 and a pharmaceutically acceptable diluent or carrier.

22. (Original) A method of treating pain, which comprises administering to a patient an effective amount of a compound of the formula:



wherein R represents C<sub>1</sub>-C<sub>20</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>1</sub>-C<sub>6</sub> alkylaryl, C<sub>1</sub>-C<sub>6</sub> alkyl(C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, C<sub>1</sub>-C<sub>6</sub> alkyl-N,N-C<sub>1</sub>-C<sub>6</sub> dialkylamine, C<sub>1</sub>-C<sub>6</sub> alkyl-pyrrolidine, C<sub>1</sub>-C<sub>6</sub> alkyl-piperidine, C<sub>1</sub>-C<sub>6</sub> alkyl-morpholine or a pharmaceutically acceptable salt thereof.

23. (Original) A method of treating migraine, which comprises administering to a patient an effective amount of a compound of the formula:



wherein R represents C<sub>1</sub>-C<sub>20</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>1</sub>-C<sub>6</sub> alkylaryl, C<sub>1</sub>-C<sub>6</sub> alkyl(C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, C<sub>1</sub>-C<sub>6</sub> alkyl-N,N-C<sub>1</sub>-C<sub>6</sub> dialkylamine, C<sub>1</sub>-C<sub>6</sub> alkyl-pyrrolidine, C<sub>1</sub>-C<sub>6</sub> alkyl-piperidine, C<sub>1</sub>-C<sub>6</sub> alkyl-morpholine or a pharmaceutically acceptable salt thereof.

24. (Cancelled)

25. (Cancelled)